Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series.
The efficacy and tolerability of symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD) was evaluated in an open trial. Eight outpatients, aged 18-45 years and diagnosed with PMDD, were treated with 10-20 mg of citalopram from the start of premenstrual symptoms until the onset of menses. Primary efficacy variables were the premenstrual tension scale (PMTS-O) and the clinical global impression of improvement (CGI). Treatment was associated with significant improvement in PMDD symptoms (p < 0.001).
Ravindran
L N
LN
Department of Psychiatry, University of Toronto, Toronto, Canada. arun_ravindran@camh.net
Woods
S-A
SA
Steiner
M
M
Ravindran
A V
AV
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage*; D015283:Citalopram / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008183:Luteal Phase / Q000187:drug effects; D008875:Middle Aged; D017060:Patient Satisfaction; D011293:Premenstrual Syndrome / Q000188:drug therapy* / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D012107:Research Design; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage*; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation; D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors